title: Reply to Soteriadou et al.
authors.affiliation: 1Department of Internal Medicine, Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 2Department of Internal Medicine, Division of Gastroenterology and Hepatology, William Beaumont Hospital, Royal Oak, Michigan 3Department of Internal Medicine, Division of Infectious Diseases, Mayo Clinic, Rochester, Minnesota.
authors.forename: Maneesh
authors.initials: M
authors.lastname: Dave
authors.forename: Treta
authors.initials: T
authors.lastname: Purohit
authors.forename: Raymund R
authors.initials: RR
authors.lastname: Razonable
authors.forename: Edward V
authors.initials: EV
authors.lastname: Loftus
mesh_terms: D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy*; D009894:Opportunistic Infections / Q000139:chemically induced*
chemical_list: D007166:Immunosuppressive Agents